2WHO,The Selection of Essential Medicines. Geneva: Policy Perspectives on Medicines,World Health Organisation, 2002, p.1. 被引量：1
3Najmi Kanji(ed. ),Drugs Policy in Developing Countries. London:Zed Books,1992. 被引量：1
4WHO, Equitable access to essential medicines : a framework for collective action.Geneva:Policy Perspectives on Medicines, World Health Organisation,2004. 被引量：1
6[1]Zhou EY.Chinese biogenerics and protection of IP.Genet Eng News,2006,26(15),56-60. 被引量：1
7[2]Wu DW.US regulatory and scientific perspectives on follow-on biologics:report on seminar of biosimilars,bring follow-on biologics to market.Zurich:IBC Life Sciences,2006. 被引量：1
8[3]Europa.Biotech medicines:first biosimilar drug on EU market[EB/OL].(2006-04-20)[2006-09-11].http://europa.eu/rapid/pressReleasesAction.do?reference=IP/06/511&format=HTML&aged=0&language=EN&guiLanguage=en. 被引量：1
9[5]European medicines agency.Guideline on similar biological medicinal products[EB/OL].(2006-10-30)[2006-09-11].http://www.ebe-efpia.org/docs/pdf/Biosim_overarching.pdf. 被引量：1
10[6]European medicines agency.Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:quality issues[EB/OL].(2006-02-22)[2006-09-11].http://www.emea.eu.int/pdfs/human/biosimilar/4934805en.pdf. 被引量：1
